Table 3 Long-term assessment of patients... | American Society of Hematology

Table 3

Long-term assessment of patients with ALPS-related symptoms present < 15 years and with a follow-up of > 20 years (N = 42)

Less than 15 years, n (%)*	More than 20 years, n (%)†
Lymphoproliferation 42 (100)	Complete remission	28 (66)
	Improvement	14 (34)
Autoimmunity 25 (59)	Complete remission	11 (44)
	Persistent	14 (56)
Treatment 26 (48)	Stopped	12 (46)
	Persistent	14 (54)

Less than 15 years, n (%)*	More than 20 years, n (%)†
Lymphoproliferation 42 (100)	Complete remission	28 (66)
	Improvement	14 (34)
Autoimmunity 25 (59)	Complete remission	11 (44)
	Persistent	14 (56)
Treatment 26 (48)	Stopped	12 (46)
	Persistent	14 (54)

Median age at onset, 3 y (range: 0-14).

Median follow-up time, 28 y (range: 20.5-77).